drugset / Trial / NCT05083182

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

NCT05083182

Phase 3 Active not recruiting 50 enrolled Janssen Research & Development, LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).

Timeline

Start
2022-08-30
Primary completion
2026-01-12
Completion
2026-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Guselkumab Monoclonal antibody Subcutaneous
Subject Ustekinumab Monoclonal antibody Subcutaneous